Exploration of Immunology

Table 1. Baseline characteristics of CHB patients and healthy controls.

Characteristic	CHB (n = 90)	Controls (n = 100)	P-value
Age, years	35 (27–45)	34 (26–44)	0.41
Male sex, n (%)	49 (54)	52 (52)	0.78
BMI, kg/m²	25.3 ± 3.1	24.9 ± 2.8	0.33
ALT, IU/L	46 (25–89)	22 (18–27)	< 0.001
AST, IU/L	42 (23–81)	21 (17–25)	< 0.001
Platelets, × 10⁹/L	230 (159–310)	275 (242–320)	< 0.001
HBV DNA, log₁₀ IU/mL	6.1 (3.2–7.8)	—	—
HBeAg-positive, n (%)	50 (56)	—	—
LSM, kPa	7.4 (4.8–12.1)	4.3 (3.9–4.9)	< 0.001
CAP, dB/m	245 (210–278)	238 (220–255)	0.09

Return to article view

Data presented as median [interquartile range (IQR)] or mean ± SD. ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; CAP: controlled attenuation parameter; HBeAg: hepatitis B e-antigen; HBV: hepatitis B virus; LSM: liver stiffness measurement.

Supplementary materials

The supplementary tables for this article are available at: https://www.explorationpub.com/uploads/Article/file/1003270_sup_1.pdf.

Declarations

Acknowledgments

The authors gratefully acknowledge the contributions of the nursing and laboratory personnel at the participating hospitals for their invaluable assistance in patient recruitment and specimen processing.

Author contributions

ZNA: Conceptualization, Methodology, Investigation, Formal analysis, Writing—original draft. MAK: Conceptualization, Supervision, Validation, Writing—review & editing. YHM: Resources, Data curation, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Ethical approval

The study protocol was approved by the Scientific and Ethical Committee of the Iraqi Board for Medical Specializations (Ref. 2023-HEP-11), an institution distinct from the funding body; the shared “HEP-11” suffix reflects independent departmental coding and is coincidental. Supporting documentation is available on request. This study complies with the Declaration of Helsinki.

Consent to participate

Informed consent to participation in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

The datasets supporting the findings of this study are available from the corresponding author upon reasonable request.

Funding

This work was supported by grant No. 2024-HEP-11 from the Ministry of Higher Education and Scientific Research, Republic of Iraq. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Burki T. WHO’s 2024 global hepatitis report. Lancet Infect Dis. 2024;24:e362–e3. [DOI] [PubMed]

Wang L, Wang J, Zhao K, Jiang L, Zhang X, Zhao J, et al. The Relationship between Viral Replication and the Severity of Hepatic Necroinflammatory Damage Changed before HBeAg Loss in Patients with Chronic Hepatitis B Virus Infection. J Clin Transl Hepatol. 2024;12:381–8. [DOI] [PubMed] [PMC]

Liguori A, Zoncapè M, Casazza G, Easterbrook P, Tsochatzis EA. Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2025;10:332–49. [DOI] [PubMed]

Lai JC, Liang LY, Wong GL. Noninvasive tests for liver fibrosis in 2024: are there different scales for different diseases? Gastroenterol Rep. 2024;12:goae024. [DOI] [PubMed] [PMC]

Huong NTC, Hai NP, Van Khanh C, Kamel MG, Vinh Chau NV, Truong NT, et al. New biomarkers for liver involvement by dengue infection in adult Vietnamese patients: a case-control study. BMC Infect Dis. 2024;24:800. [DOI] [PubMed] [PMC]

Zhang Z, Wang J, Li H, Niu Q, Tao Y, Zhao X, et al. The role of the interleukin family in liver fibrosis. Front Immunol. 2025;16:1497095. [DOI] [PubMed] [PMC]

Dewidar B, Meyer C, Dooley S, Meindl-Beinker AN. TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019. Cells. 2019;8:1419. [DOI] [PubMed] [PMC]

Dimitriadis K, Katelani S, Pappa M, Fragkoulis GE, Androutsakos T. The Role of Interleukins in HBV Infection: A Narrative Review. J Pers Med. 2023;13:1675. [DOI] [PubMed] [PMC]

Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. miR-122 – A key factor and therapeutic target in liver disease. J Hepatol. 2015;62:448–57. [DOI] [PubMed]

10.

Trebicka J, Anadol E, Elfimova N, Strack I, Roggendorf M, Viazov S, et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol. 2013;58:234–9. [DOI] [PubMed]

11.

Appourchaux K, Dokmak S, Resche-Rigon M, Treton X, Lapalus M, Gattolliat CH, et al. MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C. Sci Rep. 2016;6:34935. [DOI] [PubMed] [PMC]

12.

Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection [Internet]. WHO; c2026 [cited 2026 Aug 10]. Available from: https://www.who.int/publications/i/item/9789240090903

13.

European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98. [DOI] [PubMed]

14.

Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99. [DOI] [PubMed]

15.

Xu W, Hu Q, Chen C, Li W, Li Q, Chen L. FibroScan Predicts Liver Fibrosis Progression in Chronic HBV Infection Patients with No Clear Indication for Antiviral Therapy: A Retrospective Cohort Study. Infect Drug Resist. 2023;16:1777–85. [DOI] [PubMed] [PMC]

16.

Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343–50. [DOI] [PubMed]

17.

Abdelkareem Abakar MA, Hussein Ali AA, Ahmed Elhassan ED, Hamuda Altaher EA, Abdalbasit Musa NH, Kafi SK, et al. Association of TNF-α, IFN-γ, IL-6, and IL-10 with different clinical manifestations of hepatitis B infection. Ital J Med. 2023;17:e17. [DOI]

18.

Kaur N, Garg R, Tapasvi C, Goyal G. Micro RNAs as a potential biomarker for predicting liver fibrosis severity in hepatitis C virus affected patients. World J Virol. 2025;14:101976. [DOI] [PubMed] [PMC]

19.

Chen J, Yu S, Lang Z, Jin Y, Zhou G, Tao Q, et al. Development and validation of a potential biomarker to improve the assessment of liver fibrosis progression in patients with chronic hepatitis B. J Med Virol. 2022;95:e28239. [DOI] [PubMed]

20.

Easterbrook PJ, Luhmann N, Bajis S, Min MS, Newman M, Lesi O, et al. WHO 2024 hepatitis B guidelines: an opportunity to transform care. Lancet Gastroenterol Hepatol. 2024;9:493–5. [DOI] [PubMed]

21.

Lim YS, Kim WR, Dieterich D, Kao JH, Flaherty JF, Yee LJ, et al. Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B. Viruses. 2023;15:997. [DOI] [PubMed] [PMC]

22.

Ribeiro TCR, de Paula Boechat Soares V, Campos Fabri J, de Aragão Ramos LE. Noninvasive liver fibrosis assessment in metabolic dysfunction-associated steatotic liver disease. World J Hepatol. 2026;18:111534. [DOI] [PubMed] [PMC]

23.

Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486–99. [DOI] [PubMed] [PMC]

24.

Liu S, Zhou B, Valdes JD, Sun J, Guo H. Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection. Hepatology. 2019;69:1816–27. [DOI] [PubMed] [PMC]